Brazil's Ministry of Health announced Thursday that the country is expected to import a U.S. technology for producing anti-dengue-fever vaccine.
Reinaldo Guimaraes, the ministry's secretary of science, technology and energy supplies, told the media that the governmenth as charged the Sao Paulo-headquartered Butantan Institute to negotiate with U.S. researchers who have been developing anti-dengue-fever vaccine for a deal to purchase the technology.
He said he will study the possibility of getting a loan from the country's National Economic and Social Development Bank to buy the technology.
Guimaraes said the U.S. researchers have not developed a "ready" vaccine and in experiments on animals and humans, the vaccine has shown "promising" results, but it still needs "three or four years" to prove its full effectiveness.
He said if the technology is acquired, the Butantan Institute will be charged with the task to improve the technology.
Dengue fever is a viral infection spread by the Aedes Aegypti mosquito. Most mainstream dengue cases are not fatal, but the hemorrhagic variant, which causes severe internal bleeding as blood vessels collapse, kills one in 20 of the infected.
Source:Xinhua
|
Comment
Tell A Friend
Print Format
Save Article